ReviewClinical Medicine Insights. Cardiology2020
Ventricular Arrhythmias in Cardiac Amyloidosis: A Review of Current Literature.
Review in Clinical Medicine Insights. Cardiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 42 citations in OpenAlex.
- Sustained Ventricular Tachycardia as the First Presentation of Hereditary Transthyretin Amyloidosis With the Glu109Gln Mutation.JACC. Case reports · 2026Article
- Cardiac Implantable Electronic Devices in Oncology Patients: Challenges and Management.Journal of cardiovascular electrophysiology · 2026Review
- The Arrhythmic Burden of Cardiac Amyloidosis: A Comprehensive Review.Heart views : the official journal of the Gulf Heart Association · 2026Review
- Prognostic Factors and Implantable Cardioverter-Defibrillator Outcomes in Transthyretin Cardiac Amyloidosis: A Comprehensive Retrospective Study.Reviews in cardiovascular medicine · 2026Article
- The Vagal Link: Autonomic Nervous System Dysfunction in Cardiac Amyloidosis.Journal of clinical medicine · 2025Review
- What Cardiologists Should Know About Amyloidosis.Journal of clinical medicine · 2025Review
- Heart Failure Management in Cardiac Amyloidosis: Towards a Paradigm Shift.Cardiac failure review · 2025Review
- Monitoring for arrhythmia in transthyretin cardiac amyloidosis with noninvasive ambulatory patch devices.Heart rhythm O2 · 2024Article
- Arrhythmogenic Potential of Myocardial Edema: The Interstitial Osmolality Induces Spiral Waves and Multiple Excitation Wavelets.Biomedicines · 2024Article
- Advances in the Diagnosis and Management of Cardiac Amyloidosis: A Literature Review.Cardiology research · 2024Review
- Management of Arrhythmias and Conduction Disorders in Amyloid Cardiomyopathy.Journal of clinical medicine · 2024Review
- Multiparametric Mapping via Cardiovascular Magnetic Resonance in the Risk Stratification of Ventricular Arrhythmias and Sudden Cardiac Death.Medicina (Kaunas, Lithuania) · 2024Review
- A Novel Approach to Cardiac Magnetic Resonance Scar Characterization in Patients Affected by Cardiac Amyloidosis: A Pilot Study.Medicina (Kaunas, Lithuania) · 2024Article
- Clinical Outcomes of Percutaneous Coronary Intervention in Amyloidosis, Sarcoidosis, and Hemochromatosis.Journal of the Society for Cardiovascular Angiography & Interventions · 2024Article
- Prognostic implications of premature ventricular contractions and non-sustained ventricular tachycardia in light-chain cardiac amyloidosis.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2024Article
- Non-Cardiac Amyloidosis Findings Are Not Increased in African American Carriers ofJournal of personalized medicine · 2024Article
- Cardiac Amyloidosis Versus Other Restrictive Cardiomyopathies: A Retrospective Analysis of Cardiovascular Outcomes and Arrhythmic Burden.Clinical Medicine Insights. Cardiology · 2024Article
- The Role of Cardiovascular Magnetic Resonance Imaging in Patients with Cardiac Arrhythmias.Reviews in cardiovascular medicine · 2023Review
- Arrhythmias in Patients with Cardiac Amyloidosis: A Comprehensive Review on Clinical Management and Devices.Journal of cardiovascular development and disease · 2023Review
- Prevalence and Treatment of Arrhythmias in Patients With Transthyretin and Light-Chain Cardiac Amyloidosis.Circulation reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac Amyloidosis is an infiltrative cardiomyopathy which occurs secondary to deposition of mis-folded protein in the myocardium, with the two most common subtypes being AL amyloidosis and TTR amyloidosis. The pathogenesis of the disease is multifaceted and involves a variety of mechanisms including an inflammatory response cascade, oxidative stress and subsequent separation of myocyte fibrils. Cardiac Amyloidosis frequently results in congestive cardiac failure and arrhythmias, from a disruption in cardiac substrate with subsequent electro-mechanical remodelling. Disease progression is usually demonstrated by development of progressive pump failure, which may be seen with a high arrhythmic burden, usually portending a poor prognosis. There is a paucity of literature on the clinical implications of ventricular arrhythmias in the context of cardiac amyloidosis. The important diagnostic investigations for these patients include transthoracic echocardiography, cardiac magnetic resonance imaging and an electrophysiology study. Whilst there are no robust management guidelines, studies have indicated benefits from contemporary pharmacological therapy and case-by-case catheter ablation. There are novel directed therapies available for TTR amyloidosis that have shown to improve overall survival. The role of ICD therapy in cardiac amyloidosis is controversial, with benefits seen predominantly in early phases of the disease process. The only definitive surgical therapy includes heart transplantation, but is largely indicated for progressive decompensated heart failure (Figure 1). Further large-scale studies are required to better outline management paradigms for treating ventricular arrhythmias in cardiac amyloidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.